Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880, Matrixyl is a widely used cosmetic peptide with evidence of stimulating extracellular matrix synthesis and reducing wrinkle appearance in skin-care formulations48.
While Liraglutide works as a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880, Matrixyl is a palmitoylated pentapeptide, Pal-Lys-Thr-Thr-Lys-Ser (Pal-KTTKS), that acts as a matrikine, signaling to dermal fibroblasts to increase production of collagen, elastin, fibronectin, and other ECM components4858.
Liraglutide
GCG
Matrixyl
Not assigned in the current dataset.
Liraglutide and Matrixyl are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Liraglutide is more often discussed in the realm of Metabolic and endocrine, whereas Matrixyl is more often associated with the realm of Dermatology and aesthetics. They also influence different molecular systems, with Liraglutide tracking more closely to GLP-1 receptor while Matrixyl centers more on Extracellular matrix proteins. Liraglutide has a more synthetic analog origin, while Matrixyl is closer to synthetic design background and their development context also differs, with Liraglutide approved while Matrixyl is cosmetic grade. Their sequence patterns also diverge, with Liraglutide showing alpha-helical domain features and Matrixyl showing protein-mimetic sequence features.